Towa Pharmaceutical Co., Ltd.
Notice Regarding Recording of Non-operating Expenses (Derivative Valuation Loss)
Recorded derivative valuation loss of 2,355 million yen as non-operating expenses for the second quarter of the fiscal year ending March 2027. Impacted by currency movements and widening Japan-U.S. interest rate differentials. No reflection in consolidated earnings guidance at this time. Any necessary future revisions will be promptly disclosed.
Key Figures
- loss: 2,355 million yen
AI要約
Accounting Policy and Impact
According to the interim financial summary disclosed today, a derivative valuation loss will be recorded as non-operating expenses in the second quarter of the fiscal year ending March 2027. The causes are a trend toward a stronger yen and a widening long-term interest rate differential between Japan and the United States. The company does not include derivative valuation gains or losses in its consolidated earnings guidance, and states that it will promptly disclose any future revisions if they occur.
Earnings Outlook and Future Response
The consolidated earnings guidance for the fiscal year ending March 2027 has not been specially revised since it was announced on May 14, 2026, and due to uncertainty in the foreign exchange market, derivative valuation gains and losses are not incorporated into the forecasts. If a revision becomes necessary in the future, the company will promptly notify stakeholders.
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
